Sugi Predict

Sugi Predict / Compounds / SCHEMBL358661

SCHEMBL358661

SCHEMBL358661

CC1(N)CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HDAC2 Q92769 2/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SCD5 Q86SK9 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ NR1H2 P55055 1/20 0.39
▸ ACACB O00763 2/20 0.38
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17163075 1.00 USP2 (0.46) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL15797058 1.00 USP2 (0.46) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL25741844 0.90 HPGD (0.44) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL30922802 0.90 HPGD (0.44) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL359549 0.90 HPGD (0.44) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL182080 0.89 USP2 (0.53) USP2SMN1; SMN2HDAC2HPGDEPHX2
SCHEMBL30922845 0.89 HPGD (0.47) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL31040999 0.89 HPGD (0.47) USP2SMN1; SMN2HDAC2CYP11B2USP30
SCHEMBL14738914 0.85 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2NR1H2
SCHEMBL4210880 0.84 USP2 (0.50) USP2SMN1; SMN2HDAC2CYP11B2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2026-05-26 — — US disclosed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 — — EP disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
CN-120081832-A Novel sodium channel regulator 南京清普生物科技有限公司 2025-06-03 — — CN disclosed
WO-2025096637-A1 SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2025-05-08 — — WO disclosed
US-20250115587-A1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2025-04-10 — — US disclosed
CN-119654322-A TYK2 inhibitors 渤健马萨诸塞州股份有限公司 2025-03-18 — — CN disclosed
US-12234227-B2 Pyrazole derivatives as H4 antagonist compounds NXERA PHARMA UK LIMITED (GB) 2025-02-25 — — US disclosed
EP-4472974-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Schrödinger, Inc. (US) 2024-12-11 — — EP disclosed
CN-118974038-A Heterocyclic compounds and methods of use 薛定谔公司 2024-11-15 — — CN disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 — — EP disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 — — US disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 — — US disclosed
US-20140206663-A1 TRIAZINONE COMPOUNDS WUXI APPTECH (SHANGHAI) CO., LTD. (CN) 2014-07-24 — — US disclosed
WO-2014089904-A1 TRIAZINONE COMPOUNDS ABBVIE INC. (US) 2014-06-19 — — WO disclosed
WO-2014089904-A1 TRIAZINONE COMPOUNDS ABBVIE INC. (US) 2014-06-19 — — WO disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 — — US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 — — WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 — — US disclosed
WO-2012006958-A1 AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY(ADP-RIBOSE)POLYMERASE INHIBITORS ZHEJIANG BETA PHARMA INC. (CN) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234227-B2 Pyrazole derivatives as H4 antagonist compounds HRH4, HRH3, HRH2 USP2 4536/4885SMN1; SMN2 4592/4885HDAC2 20/4885
US-20140206663-A1 TRIAZINONE COMPOUNDS THPO, IL5, CYP11B2 USP2 4871/4885SMN1; SMN2 3158/4885HDAC2 691/4885
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 USP2 1293/4885SMN1; SMN2 1067/4885HDAC2 726/4885
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 USP2 1510/4885SMN1; SMN2 4803/4885HDAC2 1556/4885
US-12637426-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP1, USP10 USP2 8/4885SMN1; SMN2 2487/4885HDAC2 1609/4885
US-20250115587-A1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS HRH4, HRH3, HDAC3 USP2 4340/4885SMN1; SMN2 3906/4885HDAC2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.